NCCN Receives $2-Million Funding Commitment From ImmunoGen, Inc. to Study Mirvetuximab Soravtansine for Folate Receptor Alpha-Positive Cancers
The NCCN Oncology Research Program (ORP) Has Received a $2-Million Grant From ImmunoGen, Inc. to Facilitate Preclinical and Clinical Research With Mirvetuximab Soravtansine for Folate Receptor Alpha-Positive Cancers at NCCN Member Institutions and Their Affiliate Community Hospitals
